- Home
- NVT vs ILMN Comparison
NVT vs ILMN Comparison
Compare NVT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- ILMN
- Stock Information
- Founded
- NVT 1903
- ILMN 1998
- Country
- NVT United Kingdom
- ILMN United States
- Employees
- NVT N/A
- ILMN N/A
- Industry
- NVT Industrial Machinery/Components
- ILMN Medical Specialities
- Sector
- NVT Industrials
- ILMN Health Care
- Exchange
- NVT Nasdaq
- ILMN Nasdaq
- Market Cap
- NVT 11.5B
- ILMN 13.1B
- IPO Year
- NVT N/A
- ILMN 2000
- Fundamental
- Price
- NVT $73.48
- ILMN $100.34
- Analyst Decision
- NVT Strong Buy
- ILMN Buy
- Analyst Count
- NVT 9
- ILMN 16
- Target Price
- NVT $70.33
- ILMN $126.88
- AVG Volume (30 Days)
- NVT 1.7M
- ILMN 2.3M
- Earning Date
- NVT 08-05-2025
- ILMN 08-05-2025
- Dividend Yield
- NVT 1.09%
- ILMN N/A
- EPS Growth
- NVT 1.65
- ILMN N/A
- EPS
- NVT 3.49
- ILMN N/A
- Revenue
- NVT $3,083,300,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- NVT $19.79
- ILMN N/A
- Revenue Next Year
- NVT $9.30
- ILMN $3.11
- P/E Ratio
- NVT $21.01
- ILMN N/A
- Revenue Growth
- NVT 15.90
- ILMN N/A
- 52 Week Low
- NVT $41.71
- ILMN $68.70
- 52 Week High
- NVT $81.55
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- NVT 68.17
- ILMN 79.97
- Support Level
- NVT $71.30
- ILMN $88.68
- Resistance Level
- NVT $74.75
- ILMN $95.99
- Average True Range (ATR)
- NVT 1.70
- ILMN 2.93
- MACD
- NVT 0.00
- ILMN 0.82
- Stochastic Oscillator
- NVT 82.72
- ILMN 95.92
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.